Nutritional Formulation to Target Muscle Loss in CKD Patients

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$100,000.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK084691-01
Agency Tracking Number:
DK084691
Solicitation Year:
2009
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2009-2
Small Business Information
HEALTHSPAN SOLUTIONS, LLC
4301 W MARKHAM ST, SLOT 807, LITTLE ROCK, AR, 72205
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
809699478
Principal Investigator:
ARNY FERRANDO
(501) 526-5711
AFERRANDO@UAMS.EDU
Business Contact:
(501) 352-7746
john.troup@the-healthspan.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Hypoalbuminemia and muscle wasting are important predictors of mortality and morbidity in patients with latter stage chronic kidney disease (CKD). The persistent loss of muscle results from alterations in basal muscle protein metabolism or changes precipitated by hemodialysis (HD). A reduced synthesis of muscle proteins was noted in patients with CKD. We have repeatedly demonstrated the anabolic capacity of a formulation of essential amino acids (EAA) and have developed a supplement designed to maintain muscle mass and function in the elderly. BeneVia(R) is protected under intellectual property and has several advantages over existing products, namely, it is juice based, provides essential ingredients in a small volume (less than 7 oz), is low calorie, and is conveniently packaged. However, further refinement of this product is necessary to address the specific needs of CKD patients. BeneVia(R) Renal will be marketed as a nutritional supplement designed to maintain muscle mass and function and to minimize the catabolic effects of repeated bouts of HD. Accordingly; ingredients are targeted to ameliorate cytokine production and blood acidity. In this Phase 1 application, the general goal will be to determine if the BeneVia(R) Renal formulation stimulates muscle protein synthesis in advanced stage CKD patients to a greater extent than a commonly used formula. We hypothesize that a single dose (6oz or 177ml) of BeneVia(R) Renal will significantly stimulate muscle protein synthesis in CKD patients. Further, we hypothesize that a single dose of BeneVia(R) Renal will stimulate muscle protein synthesis to a greater extent than a single dose (8oz or 237ml) of a popular nutritional therapy designed for dialysis patients (Nepro(R)). Two groups of 12 patients will be randomly assigned to receive either BeneVia(R) Renal or Nepro(R) for 2 weeks prior to a metabolic study utilizing stable isotope methodology to determine muscle protein synthesis. A nutritional formula designed to restore optimal protein metabolism will offset the metabolic alterations that occur during the latter stages of CKD and ameliorate the loss of muscle protein and functional decline. PUBLIC HEALTH RELEVANCE: This proposal describes a nutritional supplement designed to ameliorate the catabolism of advanced CKD. If successful, the result is an economical nutritional product that can be utilized to prevent declines in function and morbidity with renal disease. This will not only improve quality of life in CKD patients, but have a significant impact on overall health care costs.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government